Cargando…

ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes

INTRODUCTION: FNA is the optimal test for classifying concerning thyroid nodules. Approximately 15-30% of FNAs are indeterminate, representing diagnostic challenge with intra- and inter-observer variability among cytologists. The Bethesda System (BS) for cytopathology was created in 2007 to standard...

Descripción completa

Detalles Bibliográficos
Autores principales: LaRoe, Matthew, Godfrey, Sean, Kalia-Reynolds, Shelly, Sheth, Krupa, Yesaulava, Mila, Demirtas, Esra, Drake, Almond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625447/
http://dx.doi.org/10.1210/jendso/bvac150.1574
_version_ 1784822498890612736
author LaRoe, Matthew
Godfrey, Sean
Kalia-Reynolds, Shelly
Sheth, Krupa
Yesaulava, Mila
Demirtas, Esra
Drake, Almond
author_facet LaRoe, Matthew
Godfrey, Sean
Kalia-Reynolds, Shelly
Sheth, Krupa
Yesaulava, Mila
Demirtas, Esra
Drake, Almond
author_sort LaRoe, Matthew
collection PubMed
description INTRODUCTION: FNA is the optimal test for classifying concerning thyroid nodules. Approximately 15-30% of FNAs are indeterminate, representing diagnostic challenge with intra- and inter-observer variability among cytologists. The Bethesda System (BS) for cytopathology was created in 2007 to standardize thyroid cytology with corresponding malignancy risk. Our goal is to identify the incidence of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/ FLUS) and the percent of malignant AUS/FLUS cases at our institution. METHODS: Chart review of 3068 adult patients with FNA performed from 2003 to 2015 was completed, with attention to reports considered "indeterminant". BS for reporting thyroid cytology was not in use at our institution during that time. Cytopathology reports were evaluated for key descriptors concerning for AUS, FLUS, or follicular neoplasm. RESULTS: 461 cytology reports included language consistent with possible "indeterminate" cytology. These reports were reviewed with our institution's cytopathologist and retrospectively assigned an equivalent BS category. 241 cases were consistent with BS category III (7.86% of all thyroid nodule FNAs done during this time period). Molecular marker studies were not being performed at our institution on indeterminate thyroid cytology specimens during this time period. Of the patients who had indeterminate cytology consistent with BS category III, 66.3% (160/241) went for surgery. The malignancy rate was 27.5% (44/160) in the BS category III group. CONCLUSION: Our data demonstrated that category III nodules in some practice settings may have a higher risk of malignancy than traditionally believed, and that guidelines recommending repeat FNA or observation merit reconsideration. Molecular marker testing on indeterminate thyroid cytology specimens has been shown to be helpful in determining cases for surgery and is now being utilized at our institution. Presentation: No date and time listed
format Online
Article
Text
id pubmed-9625447
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96254472022-11-14 ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes LaRoe, Matthew Godfrey, Sean Kalia-Reynolds, Shelly Sheth, Krupa Yesaulava, Mila Demirtas, Esra Drake, Almond J Endocr Soc Thyroid INTRODUCTION: FNA is the optimal test for classifying concerning thyroid nodules. Approximately 15-30% of FNAs are indeterminate, representing diagnostic challenge with intra- and inter-observer variability among cytologists. The Bethesda System (BS) for cytopathology was created in 2007 to standardize thyroid cytology with corresponding malignancy risk. Our goal is to identify the incidence of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/ FLUS) and the percent of malignant AUS/FLUS cases at our institution. METHODS: Chart review of 3068 adult patients with FNA performed from 2003 to 2015 was completed, with attention to reports considered "indeterminant". BS for reporting thyroid cytology was not in use at our institution during that time. Cytopathology reports were evaluated for key descriptors concerning for AUS, FLUS, or follicular neoplasm. RESULTS: 461 cytology reports included language consistent with possible "indeterminate" cytology. These reports were reviewed with our institution's cytopathologist and retrospectively assigned an equivalent BS category. 241 cases were consistent with BS category III (7.86% of all thyroid nodule FNAs done during this time period). Molecular marker studies were not being performed at our institution on indeterminate thyroid cytology specimens during this time period. Of the patients who had indeterminate cytology consistent with BS category III, 66.3% (160/241) went for surgery. The malignancy rate was 27.5% (44/160) in the BS category III group. CONCLUSION: Our data demonstrated that category III nodules in some practice settings may have a higher risk of malignancy than traditionally believed, and that guidelines recommending repeat FNA or observation merit reconsideration. Molecular marker testing on indeterminate thyroid cytology specimens has been shown to be helpful in determining cases for surgery and is now being utilized at our institution. Presentation: No date and time listed Oxford University Press 2022-11-01 /pmc/articles/PMC9625447/ http://dx.doi.org/10.1210/jendso/bvac150.1574 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
LaRoe, Matthew
Godfrey, Sean
Kalia-Reynolds, Shelly
Sheth, Krupa
Yesaulava, Mila
Demirtas, Esra
Drake, Almond
ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title_full ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title_fullStr ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title_full_unstemmed ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title_short ODP474 Critical Analysis of the Thyroid Cytopathologic Diagnosis of Atypia of Undetermined Significance and Associated Clinical Outcomes
title_sort odp474 critical analysis of the thyroid cytopathologic diagnosis of atypia of undetermined significance and associated clinical outcomes
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625447/
http://dx.doi.org/10.1210/jendso/bvac150.1574
work_keys_str_mv AT laroematthew odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT godfreysean odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT kaliareynoldsshelly odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT shethkrupa odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT yesaulavamila odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT demirtasesra odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes
AT drakealmond odp474criticalanalysisofthethyroidcytopathologicdiagnosisofatypiaofundeterminedsignificanceandassociatedclinicaloutcomes